Qi Lu Wan Bao·2025-12-29 10:59Core Viewpoint - Xinhua Pharmaceutical's oseltamivir phosphate dry suspension has been approved for market launch by the National Medical Products Administration, marking a significant milestone for the company in the oral antiviral market for influenza [1][2]. Group 1: Product Approval and Market Impact - Oseltamivir phosphate is a selective neuraminidase inhibitor effective against both influenza A and B viruses, suitable for treatment and prevention in adults and children aged 2 weeks and older [1]. - The product is recognized as the first approved oral antiviral drug for influenza in China, filling a gap in the company's product line and enhancing its strategic positioning in the antiviral treatment sector [2]. - The estimated sales revenue for oseltamivir phosphate formulations in Chinese public medical institutions is approximately RMB 5.9 billion for 2024 [1]. Group 2: Clinical Significance and Usage - The dry suspension formulation is expected to become a primary treatment option for pediatric influenza due to its lower gastrointestinal side effects and ease of administration for young children [2]. - The product's design allows for precise dosage control, making it a flexible and convenient choice for influenza prevention and treatment in children [2].